logo

Redhill Biopharma Ltd. (RDHL)



Trade RDHL now with
  Date
  Headline
8/14/2018 10:16:56 AM RedHill Biopharma Announces Closing Of $25 Mln Underwritten Offering
8/13/2018 7:06:53 AM RedHill Biopharma Gets Allowance For New U.S. Patent Covering RHB-104 For Crohn’s Disease And RHB-204 For NTM Infections
8/9/2018 9:09:46 AM RedHill Biopharma Reports Pricing Of $25 Mln Underwritten Offering
7/30/2018 7:06:37 AM RedHill Announces Positive Top-line Safety, Efficacy Results From First Phase III Study With RHB-104 For Crohn’s Disease
7/23/2018 7:15:33 AM RedHill Biopharma Announces Uplisting To Nasdaq Global Market
7/2/2018 7:03:26 AM RedHill Gets Notices Of Allowance For Two New Patents Covering RHB-104 In The U.S. And Europe
6/28/2018 9:11:24 AM RedHill Biopharma Enters Co-promotion Agreement With Napo
5/29/2018 8:03:38 AM RedHill Biopharma Announces New U.S. Patent For Its Experimental Ebola Therapy
5/8/2018 7:13:53 AM RedHill Biopharma Q1 Net Revenues $2.4 Mln, An Increase Of 22%
4/9/2018 7:15:50 AM RedHill Biopharma Provides Semi-Annual Business Update; Q4 Net Revenues $2 Mln
3/27/2018 8:14:25 AM RedHill Biopharma Says Two Oral Presentations On BEKINDA 24 Mg For Acute Gastroenteritis At SAEM 2018 Annual Meeting
3/26/2018 8:10:17 AM RedHill Biopharma Says DDW 2018 Poster Of Distinction On Positive Phase II Results With BEKINDA For IBS-D
3/19/2018 7:07:36 AM RedHill Biopharma Announces Poster Presentation On New Potential Therapeutic Applications Of RHB-107 At AACR
2/22/2018 7:23:49 AM RedHill Biopharma Q4 Loss Per Share $0.26 Vs Loss $0.24 Last Year
  
 
>